Anagliptin

Overview

Anagliptin is under investigation for the treatment of LDL Cholesterol, Coronary Disease, Diabetes Mellitus, Glycosylated Hemoglobin, and Dipeptidyl-Peptidase 4 Inhibitors.

Background

Anagliptin is under investigation for the treatment of LDL Cholesterol, Coronary Disease, Diabetes Mellitus, Glycosylated Hemoglobin, and Dipeptidyl-Peptidase 4 Inhibitors.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
MAGE of Anagliptin Compared With Sitagliptin With Type 2 Diabetes Mellitus	2021/03/23	NCT04810507	Phase 4	Completed	JW Pharmaceutical
Korean Observational Study to Evaluate the Efficacy and Safety of Anagliptin Switching From Other DPP4is in type2 DM	2020/02/13	NCT04267601	N/A	UNKNOWN	JW Pharmaceutical
Randomized Evaluation of Anagliptin Versus Sitagliptin On Low-density lipoproteiN Cholesterol in Diabetes Trial	2015/01/05	NCT02330406	Phase 4	Completed	Institute for Clinical Effectiveness, Japan
Efficacy and Safety of CWP-0403 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin Alone	2012/02/09	NCT01529541	Phase 3	Completed	JW Pharmaceutical
A Study to Efficacy and Safety of CWP-0403 in Type 2 Diabetes Mellitus Patients	2012/02/09	NCT01529528	Phase 3	Completed	JW Pharmaceutical
A Study Comparing the Safety, Tolerance, and Efficacy of Various Doses of SK-0403 Versus Placebo and Sitagliptin 100 mg in Patients Not Well-Controlled on Metformin Therapy	2010/07/23	NCT01169090	Phase 2	Completed	Kowa Research Institute, Inc.
A Multicenter, Open Label, Single Dose Study to Evaluate the Effect of Renal Insufficiency on the Pharmacokinetics of SK 0403	2010/05/26	NCT01131091	Phase 1	Completed	Kowa Research Institute, Inc.
Phase II Dose-Finding Study of SK-0403 With Type 2 Diabetes Mellitus	2007/09/20	NCT00532506	Phase 2	Completed	Sanwa Kagaku Kenkyusho Co., Ltd.

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Related News

No news found

AI-Powered Research

Premium Access